Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
Moderna has initiated a Phase 3 study for its investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, with the first participants dosed in the U.S. and UK. This study, supported by CEPI, aims to evaluate the vaccine’s safety and immunogenicity in healthy adults, strengthening global pandemic preparedness against H5 influenza. Moderna has also committed to allocating 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries if the vaccine is licensed.